GlassScriptPhysician profile
Lester P Trapp
NPI 1932386182
$2,559.98
in general payments reported to CMS, 2019-2025
29 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $337 · 2022: $559 · 2023: $337 · 2024: $770 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $476.62 | 2021-2024 | Senza |
| Collegium Pharmaceutical, INC. | $411.16 | 2021-2025 | Xtampza, Belbuca |
| Medtronic, INC. | $195.38 | 2025 | Inceptiv, Kyphon Express II Kyphopak Tray, Synchromedii |
| Biotronik Nro, INC. | $176.16 | 2023-2025 | Biotronik, Prospera |
| Stryker Corporation | $172.01 | 2024 | Mild Device Kit |
| Forte Bio-Pharma LLC | $168.19 | 2021-2024 | Prolate, Nalocet |
| Relievant Medsystems, INC. | $151.52 | 2022 | |
| Grt US Holding, INC. | $124.80 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.14 | 2021-2025 | Relistor |
| Almatica Pharma LLC | $79.94 | 2021-2023 | Gralise |
| Foundation Fusion Solutions, LLC | $58.85 | 2025 | |
| Saluda Medical Americas, INC. | $48.51 | 2025 | Evoke |
| Trevena, INC. | $45.16 | 2023 | Olinvyk |
| Averitas Pharma INC. | $40.23 | 2024-2025 | Qutenza |
| Abbvie INC. | $32.48 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $31.80 | 2024-2025 | Horizant |
| Spinal Simplicity, LLC | $29.57 | 2024 | Ha Minuteman G3-R |
| Biodelivery Sciences International, INC. | $26.29 | 2021 | |
| Abbott Laboratories | $25.61 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $22.52 | 2025 | Iovera, Zilretta |
| Tersera Therapeutics LLC | $21.55 | 2021 | |
| Stimwave Technologies Incorporated | $19.26 | 2021 | |
| Convatec INC. | $17.44 | 2024 | |
| Valinor Pharma, LLC | $15.41 | 2025 | Movantik |
| Radius Health, INC. | $14.75 | 2021 | |
| Eisai INC. | $14.44 | 2021 | |
| Pfizer INC. | $14.08 | 2021 | |
| Hikma Pharmaceuticals USA | $14.07 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.04 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lester Trapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.